

# 111In

- [<sup>111</sup>In]5-[(3aR,6S,6aS)-2-Oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-6-yl]pentanoic acid
- [<sup>111</sup>In]-DOTA-Aminohexanoyl-[D-Phe<sup>6</sup>,Leu-NHCH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub><sup>13</sup>,desMet<sup>14</sup>]BBN[6-14]
- [<sup>111</sup>In]-Ethylenedicysteine-murine anti-phosphotyrosine antibody
- [<sup>111</sup>In]Labeled-(NAc-dD-CHA-F-dS-dR-Y-L-W-S-βAla)<sub>2</sub>-K-K(DOTA)
- [<sup>111</sup>In]-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-heat-stable human *Escherichia coli* enterotoxin
- [<sup>111</sup>In]-Labeled chimeric monoclonal antibody cG250 directed against carbonic anhydrase IX
- [<sup>111</sup>In]-Labeled divalent Fab fragment of chimeric monoclonal antibody cG250 directed against carbonic anhydrase IX
- [<sup>111</sup>In]-Labeled monovalent Fab fragment of chimeric monoclonal antibody cG250 directed against carbonic anhydrase IX
- [<sup>111</sup>In-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-Pro<sup>1</sup>,Tyr<sup>4</sup>]Bombesin
- [<sup>111</sup>In-1,4,7-Triazacyclononane,1-glutaric acid-4,7-acetic acid-10-maleimidoethylacetamide-Cys<sup>61</sup>]-Affibody Z<sub>HER2:2395</sub>
- [<sup>111</sup>In-Diethylenetriamine pentaacetic acid-ACMpip<sup>5</sup>,Tha<sup>6</sup>,βAla<sup>11</sup>,Tha<sup>13</sup>,Nie<sup>14</sup>]bombesin(5-14)
- [<sup>111</sup>In-Diethylenetriaminepentaacetic acid-Pro<sup>1</sup>,Tyr<sup>4</sup>]bombesin
- <sup>111</sup>In/<sup>125</sup>I/<sup>131</sup>I-Labeled anti-mucin-1 murine, chimeric or humanized antibody hPAM4
- <sup>111</sup>In/<sup>125</sup>I/<sup>99m</sup>Tc-Labeled N-terminus tri-(histidine-glutamate) (HE)<sub>3</sub>-tagged and N- or C-terminus hexahistidine (H6)-tagged anti-epidermal growth factor receptor Affibody Z<sub>HER2:342-C</sub>
- <sup>111</sup>In/<sup>86</sup>Y-Labeled F(ab')<sub>2</sub> fragment of panitumumab, a fully human monoclonal antibody directed against the extracellular domain III of the epidermal growth factor receptor
- <sup>111</sup>In-(1-isothiocyanatobenzyl-3-methyldiethylenetriaminepentaacetic acid)-anti-TAG-72 humanized C<sub>H2</sub> domain-deleted antibody

- <sup>111</sup>In-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-Ac-RWQPCPAESWT-Cha-CWDPGGGK-NH<sub>2</sub> (FibPep)
- <sup>111</sup>In-1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid-anti-insulin-like growth factor 1 receptor Affibody Z<sub>IGF1R:4551</sub>
- <sup>111</sup>In-1,4,7,10-Tetraazacyclododecane-1,4,7,10-triacetic acid-8-aminooctanoic acid-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH<sub>2</sub>
- <sup>111</sup>In-1,4,7,10-Tetraazacyclododecane-1,4,7-triacetic acid-L-homoalanine
- <sup>111</sup>In-1,4,7,10-tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide-Affibody Z<sub>HER2:2395</sub>-Cys
- <sup>111</sup>In-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-AB.Fab4D5
- <sup>111</sup>In-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid- Affibody Z<sub>HER2:342</sub>-pep2
- <sup>111</sup>In-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-cyclo(D-diaminobutyric acid-Arg-Phe-Phe-D-Trp-Lys-Thr-Phe)
- <sup>111</sup>In-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-LLP2A
- <sup>111</sup>In-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-T84.66 diabody
- <sup>111</sup>In-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-T84.66 minibody
- <sup>111</sup>In-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-T84.66 scFv-human serum albumin
- <sup>111</sup>In-1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-NDECELCVNVACTGCL
- <sup>111</sup>In-1,4,7-Triazacyclononane,1-glutaric acid-4,7-acetic acid-Glu-[cyclo(Arg-Gly-Asp-D-Phe-Lys)]<sub>2</sub>
- <sup>111</sup>In-2-(4,7,10-Tris(carboxymethyl)-1,4,7,10-tetracyclododecan-1-yl)pentanedioic acid-Trastuzumab
- <sup>111</sup>In-2-(*p*-isothiocyanatobenzyl)-6-methyl-diethylenetriamine-*N,N,N',N'',N'''*-pentaacetic acid-trastuzumab
- <sup>111</sup>In-Anti-CD105 MJ7/18 monoclonal antibody
- <sup>111</sup>In-Benzyl-diethylenetriamine pentaacetic acid-AMB8LK

- <sup>111</sup>In-Benzyl-diethylenetriaminepentaacetic acid-Z<sub>HER2:342</sub>
- <sup>111</sup>In-Benzyl-tetraazacyclododecane-*N,N,N',N''*-tetraacetic acid-Z<sub>HER2:342</sub>
- <sup>111</sup>In-BZ-Diethylenetriaminepentaacetic acid-Z<sub>EGFR:1907</sub>
- <sup>111</sup>In-Capromab pendetide
- <sup>111</sup>In-CHX-A"-DTPA-anti-mindin/RG-1 monoclonal antibody 19G9
- <sup>111</sup>In-CHX-A"-diethylenepentaacetic acid-Affibody Z<sub>HER2:2395</sub>-Cys
- <sup>111</sup>In-CHX-A"-Diethylenetriamine pentaacetic acid-(Z<sub>EGFR:955</sub>)<sub>2</sub>
- <sup>111</sup>In-CHX-A"-Rhenium-cyclized-[Cys<sup>3,4,10</sup>,D-Phe<sup>7</sup>,Arg<sup>11</sup>]α-MSH<sub>3-13</sub>
- <sup>111</sup>In conjugated to benzyl-diethylenetriaminepentaacetic acid-human epidermal growth factor
- <sup>111</sup>In-Diethylenetriaminepentaacetic acid-2-(*p*-isothiocyanatobenzyl)-6-methyl-B3 monoclonal antibody
- <sup>111</sup>In-Diethylenetriaminepentaacetic acid-2C5 monoclonal antibody
- <sup>111</sup>In-Diethylenetriaminepentaacetic acid-aminohexanoic acid-Lys<sup>40</sup>-exendin-4
- <sup>111</sup>In-Diethylenetriamine pentaacetic acid-anti-epithelial glycoprotein-1 hRS7 humanized monoclonal antibody
- <sup>111</sup>In-Diethylenetriamine pentaacetic acid-Anti-ligand-induced binding sites (LIBS) single-chain (scFv) antibody
- <sup>111</sup>In-Diethylenetriamine pentaacetic acid-bevacizumab
- <sup>111</sup>In-Diethylenetriaminepentaacetic acid-cyclo(CTTHWGFTLC)
- <sup>111</sup>In-Diethylenetriamine pentaacetic acid-human anti-insulin-like growth factor 1 receptor monoclonal antibody R1507
- <sup>111</sup>In-Diethylenetriamine pentaacetic acid-human epidermal growth factor
- <sup>111</sup>In-Diethylenetriamine pentaacetic acid-IC2 rat monoclonal autoantibody to pancreatic β-cell surface antigen
- <sup>111</sup>In-Diethylenetriaminepentaacetic acid-Lys<sup>40</sup>-exendin-3
- <sup>111</sup>In-Diethylenetriamine pentaacetic acid-NAVPNLRGDLQVLAQKVART
- <sup>111</sup>In-Diethylenetriamine pentaacetic acid-pertuzumab
- <sup>111</sup>In-Diethylenetriaminepentaacetic acid-polyethylene glycol-annexin V
- <sup>111</sup>In-Diethylenetriamine pentaacetic acid-QKYGNQWAVGHLM-NH<sub>2</sub>
- <sup>111</sup>In-Diethylenetriamine pentaacetic acid-single-walled nanotubes

- <sup>111</sup>In-Diethylenetriaminepentaacetic acid-trastuzumab
- <sup>111</sup>Indium-diethylenetriaminepentaacetic acid-D-phenylalanine-octreotide
- <sup>111</sup>Indium-diethylenetriaminepentaacetic acid-folate
- <sup>111</sup>In-DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH<sub>2</sub>
- <sup>111</sup>In-DOTA-Gly-benzoyl-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH<sub>2</sub>
- <sup>111</sup>In-DOTA-Re(Cys<sup>3,4,10</sup>,D-Phe<sup>7</sup>,Arg<sup>11</sup>)αMSH<sub>3-13</sub>
- <sup>111</sup>In-DPC11870
- <sup>111</sup>In-DTPA-Poly(ethylene glycol)-anti-epidermal growth factor receptor antibody C225
- <sup>111</sup>In-Ibritumomab tiuxetan
- <sup>111</sup>In-Labeled (7S)-26-(4-((1-((1-carboxy-5-(2-(4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-yl)acetamido)pentyl)amino)-1-oxo-6-(1-((7S)-1,3,7,22-tetracarboxy-5,13,20-trioxo-4,6,12,21-tetraazahexacosan-26-yl)-1H-1,2,3-triazole-4-carboxamido)hexan-2-yl)carbonyl)-1H-1,2,3-triazol-5-yl)-5,13,20-trioxo-4,6,12,21-tetraazahexacosane-1,3,7,22-tetracarboxylic acid
- <sup>111</sup>In-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated dimeric [Tyr<sup>3</sup>]octreotide
- <sup>111</sup>In-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated monomeric [Tyr<sup>3</sup>]octreotide
- <sup>111</sup>In-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-regioselectively addressable functionalized template-[cyclo-(Arg-Gly-Asp-D-Phe-Lys)]<sub>4</sub>
- <sup>111</sup>In-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-VENK[homoC]NKEMRNRYWEAALDPNLNNQKRAKIRSIYDDP[homoC]-NH<sub>2</sub> with a disulfide bridge between the two homoC
- <sup>111</sup>In-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-Glu{PEG<sub>4</sub>-Glu[cyclo(Lys(Gly-Gly-Gly)-Arg-Gly-Asp-D-Phe)]-cyclo(Lys(Gly-Gly-Gly)-Arg-Gly-Asp-D-Phe)}-{PEG<sub>4</sub>-Glu[cyclo(Lys(Gly-Gly-Gly)-Arg-Gly-Asp-D-Phe)]-cyclo(Lys(Gly-Gly-Gly)-Arg-Gly-Asp-D-Phe)} (PEG<sub>4</sub> = 15 amino-4,7,10,13-tetraoxapentadecanoic acid)
- <sup>111</sup>In-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-Glu{PEG<sub>4</sub>-Glu[cyclo(Lys(PEG<sub>4</sub>)-Arg-Gly-Asp-D-Phe)]-cyclo(Lys(PEG<sub>4</sub>)-Arg-Gly-Asp-D-Phe)}-{PEG<sub>4</sub>-Glu[cyclo(Lys(PEG<sub>4</sub>)-Arg-Gly-Asp-D-Phe)]-cyclo(Lys(PEG<sub>4</sub>)-Arg-Gly-Asp-D-Phe)} (PEG<sub>4</sub> = 15 amino-4,7,10,13-tetraoxapentadecanoic acid)
- <sup>111</sup>In-Labeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-Glu{PEG<sub>4</sub>-Glu[cyclo(Lys-Arg-Gly-Asp-D-Phe)]-cyclo(Lys-Arg-Gly-Asp-D-Phe)}-{PEG<sub>4</sub>-

- Glu[cyclo(Lys-Arg-Gly-Asp-D-Phe)]-cyclo(Lys-Arg-Gly-Asp-D-Phe)} (PEG<sub>4</sub> = 15 amino-4,7,10,13-tetraoxapentadecanoic acid)
- <sup>111</sup>In-Labeled 1,4,7,10-tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid (DOTA)-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH<sub>2</sub> (IMP-288)
- <sup>111</sup>In-Labeled 1,4,7,10-tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-GSC(succinimidopropionyl-EAYGWNleDF-NH<sub>2</sub>)-EAYGWNleDF-NH<sub>2</sub>
- <sup>111</sup>In-Labeled Ac-Phe-Lys(DTPA)-Tyr-Lys(DTPA)-NH<sub>2</sub> (IMP-156)
- <sup>111</sup>In-Labeled affibody ABY-025 targeting epidermal growth factor receptor 2
- <sup>111</sup>In-Labeled anti-CD44v6 chimeric monoclonal antibody U36
- <sup>111</sup>In-Labeled anti-epidermal growth factor receptor Affibody PEP09239
- <sup>111</sup>In-Labeled anti-epidermal growth factor receptor human monoclonal antibody 048-006
- <sup>111</sup>In-Labeled chimeric monoclonal antibody, ch806, targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII)
- <sup>111</sup>In-Labeled CHX-A"-DTPA-conjugated MORAb-009, a chimeric monoclonal antibody directed against mesothelin
- <sup>111</sup>In-Labeled CHX-A"-DTPA conjugated monoclonal antibody (mAb) 806 targeting the epidermal growth factor receptor deletion variant de2-7 (EGFRvIII)
- <sup>111</sup>In-Labeled diethylenetriamine-pentaacetic acid-Ac-TZ14011
- <sup>111</sup>In-Labeled DOTA-conjugated 6-aminohexanoic linker-containing variant of anti-epidermal growth factor receptor 2 Affibody Z<sub>HER2:342</sub> (ABY-003)
- <sup>111</sup>In-Labeled DOTA-conjugated sCCK8[Phe<sup>2</sup>(*p*-CH<sub>2</sub>SO<sub>3</sub>H),Nle<sup>3,6</sup>], a sulfated cholecystokinin 8 (sCCK8) peptide derivative
- <sup>111</sup>In-Labeled DTPA conjugated anti-c-kit monoclonal antibody 12A8 Fab fragment
- <sup>111</sup>In-Labeled DTPA conjugated monoclonal antibody 12A8 that targets the c-kit receptor
- <sup>111</sup>In-Labeled DTPA-conjugated Tat-linked anti-phosphorylated histone protein H2AX antibody
- <sup>111</sup>In-Labeled human serum albumin-conjugated Affibody Z<sub>HER2:342</sub> that targets the human epidermal growth factor receptor 2 (HER2)
- <sup>111</sup>In-Labeled lexatumumab
- <sup>111</sup>In-Labeled mapatumumab
- <sup>111</sup>In-Labeled MLS128 anti-Tn murine monoclonal antibody

<sup>111</sup>In-Labeled panitumumab, a fully human monoclonal antibody directed against the extracellular domain III of the epidermal growth factor receptor

<sup>111</sup>In-Labeled recombinant gelonin toxin-B lymphocyte stimulator protein fusion protein

<sup>111</sup>In-*p*-Benzyl isothiocyanate-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-14C5 monoclonal antibody

<sup>111</sup>In-Streptavidin-biotinylated  $\alpha$ -melanocyte-stimulating hormone 2.0 bacteriophage

<sup>111</sup>In-TA138

<sup>111</sup>In-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-c(D-Cys-Phe-Tyr-D-Agl<sup>8</sup>(Me,2-naphthoyl)-Lys-Thr-Phe-Cys)-OH

<sup>111</sup>In-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-Glu-[cyclo(Arg-Gly-Asp-D-Phe-Lys)]<sub>2</sub>

<sup>111</sup>In-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-Glu-{Glu-[cyclo(Arg-Gly-Asp-D-Phe-Lys)]<sub>2</sub>}<sub>2</sub>

<sup>111</sup>In-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-Glu-cyclo(Arg-Gly-Asp-D-Phe-Lys)

<sup>111</sup>In-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-MEDI-522

<sup>111</sup>In-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-Phe(4-NO<sub>2</sub>)-cyclo(D-Cys-Tyr-D-Trp-Lys-Thr-Cys)-D-Tyr-NH<sub>2</sub>

<sup>111</sup>In-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-(GSG)-ANTPCGPYTHDCPVKR

<sup>111</sup>In-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-Asp-Tyr(SO<sub>3</sub>H)-Met-Gly-Trp-Met-Asp-Phe-NH<sub>2</sub>

<sup>111</sup>In-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-D-Glu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH<sub>2</sub>

<sup>111</sup>In-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-dihistidine-norleucine peptide analog

<sup>111</sup>In-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-HHEAYGWMDf-NH<sub>2</sub> peptide

<sup>111</sup>In-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-HHHHHH-EAYGWMDf-NH<sub>2</sub> peptide

<sup>111</sup>In-Tetrameric Plectin-1 targeting peptide (4( $\beta$ AKTLLPTP-GGS(PEG5000))KKK-<sup>111</sup>In-DOTA- $\beta$ A-NH<sub>2</sub>)

<sup>111</sup>In-Trastuzumab Fab

4-[2-(3,4,5,6-Tetrahydropyrimidin-2-ylamino)ethoxy]benzoyl-2-(S)-[N-3-amino-(SCN-Bz-DOXA-<sup>111</sup>In)-neopenta-1-carbamyl]-aminoethylsulfonamino-β-alanine

Anti-mouse monoclonal antibody immunoglobulin G conjugated to GRKKRRQRRRPPQYG-diethylenetriamine pentaacetic acid-[<sup>111</sup>In]

Biotinylated anti-Tn MLS128 monoclonal antibody-streptavidin-<sup>111</sup>In-DTPA-biotin

Lys-cys-cys-tyr-ser-leu-(gly-ser-gly)-1,4,7,10-tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-<sup>111</sup>In

Single-walled carbon nanotubes-<sup>111</sup>In-1,4,7,10-tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-rituximab

TA138-conjugated <sup>111</sup>In nanoparticles